Adiponectin levels in a large pooled plaque psoriasis study population

Abstract

Background: Adiponectin is an adipocyte-secreted protein potentially relevant in the context of cardiometabolic comorbidity of psoriasis patients. Objective: This post-hoc analysis aimed to assess the impact of obesity, metabolic syndrome, psoriasis severity and treatment with secukinumab/etanercept on adiponectin. Methods: Three phase III trials in moderate to severe plaque psoriasis were included. Correlations of Psoriasis Area and Severity Index (PASI), body mass index (BMI), and associated comorbidity with adiponectin levels as well as the impact of secukinumab, etanercept, and placebo were analyzed. Results: Data of 3010 patients were included of whom 71.2% had a BMI >25. Adiponectin levels were significantly higher in patients with lower BMI (r ¼ À0.23; p < .0001) and in patients without metabolic syndrome compared to patients with higher BMI and with metabolic syndrome. PASI score was negatively associated with adiponectin levels (r ¼ À0.065; p ¼ .0004). However, the correlation was extremely weak and thus clinically irrelevant. During treatment with secukinumab or etanercept over 52 weeks adiponectin levels remained stable. Conclusion: Metabolic syndrome and BMI are key determinants of adiponectin levels in psoriasis patients. Psoriasis severity and anti-psoriatic treatment had no relevant impact on adiponectin levels.

Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters

“…In human bone-marrow mesenchymal cells, IL-17A inhibits the differentiation of adipocytes and the expression of adipokines, while in differentiated adipocytes, it amplifies lipolysis. Among obese psoriatic patients, lower levels of leptin and adiponectin can be measured; moreover, a higher PASI score corresponds to a lower adiponectin level [20][21][22]. Systemic inflammation, which causes persisting symptoms of psoriasis, has several indicators, for example, serum level of CRP, HDL-cholesterol, and Apolipoprotein-A-I.…”

Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions

“…Compared to patients with psoriasis without metabolic abnormalities, patients with psoriasis and MetS or high body mass index have significantly lower adiponectin levels. The psoriasis area and severity index (PASI) score ( 60) are negatively correlated with adiponectin levels (61,62). Overall, low serum adiponectin levels in patients with psoriasis may be the link to MetS.…”

Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity

“…Adiponectin mitigates imiquimod-induced psoriasiform dermatitis via the direct inhibition of IL-17 release from gamma delta T cells [ 146 ]. Furthermore, serum adiponectin levels are inversely correlated with skin lesion severity [ 147 , 148 ], and its levels do not always increase with the improvement in skin lesions [ 142 , 149 ]. Serum adiponectin levels exhibit a greater decrease in cases with PsA compared to cases without PsA, suggesting a closer relationship between adiponectin and systemic inflammatory responses [ 150 ].…”